For applications requiring large amounts of consistent antibody, R&D Systems hybridoma and B-cell to recombinant antibody conversion service produces a dependable supply of custom engineered monoclonal antibody. R&D Systems proprietary processes guarantee yields that provide the gram quantities required for the development of diagnostic and therapeutic reagents.
Why R&D Systems Recombinant Antibody Conversion?
R&D Systems antibodies support the industry-leading Quantikine® ELISAs
Ability to scale up to gram quantity production
A cost-effective and time-saving solution for superior antibodies
The sequence and cell line(s) can be held by a third party to guarantee supply
Consistent quality and performance over time
Available Engineering Services
Modification of the species, isotype, hinge, and Fc region
Generation of active truncated forms
Improved yield without any change in affinity
cell line expressing antibody or full-length antibody sequence
antigen for testing the recombinant antibody using direct ELISA
small aliquot of purified antibody
Conversion, small scale expression of recombinant antibody, and comparison to the original hybridoma-derived antibody by R&D Systems.
Provision of data report and sample for customer's evaluation.
Exclusive supply of purified antibody.
Sequence and cell line(s) placed with third party for storage and security.
Recombinant Antibody Conversion Custom Quote
"Conversion of our traditional monoclonal to recombinant antibody offered immortal supply of a very high quality product. We also liked the feature of the recombinant technology to be able to exchange the constant chain between different species and the ability to express the antibody as Fab fragments."